You are here: Industry Insights > PTSD

News List

Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD prnasia
July 07, 2021
Bionomics Limited is pleased to announce that it has initiated a Phase 2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in patients with Post-Traumatic Stress Disorder (PTSD) with top line results expected in 1H 2023.
MDMA-assisted therapy successful in PTSD patients europeanpharmaceuticalreview
May 12, 2021
Three sessions of MDMA-assisted talk therapy resulted in significant symptom reductions for 88 percent of patients with severe, chronic post-traumatic stress disorder (PTSD).
PPD Awarded US Army RPA Develop PTSD Drugs contractpharma
February 20, 2021
PPD, Inc., a global CRO, has been awarded Defense Health Agency funds to support a five-year Research Project Award (RPA) to develop and execute an adaptive platform clinical research trial of drug interventions to treat post-traumatic stress disorder.
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD prnasia
February 18, 2021
Bionomics Limited announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences (atai).
Artelo Biosciences Files Patent on Use of FABP5 Inhibitors for Psychological Disorders americanpharmaceuticalreview
October 29, 2020
Artelo Biosciences has filed a method of use patent with the U.S. Patent and Trademark Office (USPTO) covering the use of Fatty Acid Binding Protein 5 (FABP5) inhibitors for the treatment of psychological disorders such as anxiety and post-traumatic ...
Neither Psychotherapy Nor Medications Favored for PTSD drugs
January 02, 2020
For adults with posttraumatic stress disorder (PTSD), the evidence is insufficient to determine whether trauma-focused psychotherapy or medications are more effective for symptom reduction ...
Few Trauma Patients Assessed for Effects of PTSD, Acute Stress drugs
September 20, 2019
Few trauma patients are assessed for or educated about the potential effects of posttraumatic stress disorder (PTSD) or acute stress disorder (ASD) ...
PTSD a Risk Factor for Ovarian Cancer? drugs
September 06, 2019
Struggling with post-traumatic stress disorder (PTSD) may make a woman more vulnerable to ovarian cancer, a new study suggests.
Reduction in PTSD Symptoms Linked to Decrease in T2DM drugs
August 26, 2019
Clinically meaningful reductions in posttraumatic stress disorder (PTSD) symptoms are associated with a decrease in the risk of type 2 diabetes, according to a study published online in JAMA Psychiatry.
Addex to lead mGlu7 NAM-focused PTSD consortium pharmaceutical-technology
July 10, 2019
Swiss-headquartered Addex Therapeutics has announced it will lead a consortium to develop small molecule negative allosteric modulators (NAMs) indicated to reduce fear memory in post-traumatic stress disorder (PTSD).

Previous page 1 2 Next page